Noguchi, Emi http://orcid.org/0000-0003-0326-7555
Yamanaka, Takashi
Mukai, Hirofumi
Yamamoto, Naohito
Chung, Chi-Feng
Lu, Yen-Shen http://orcid.org/0000-0001-7461-1291
Chang, Dwan-Ying
Sohn, Joohyuk
Kim, Gun Min
Lee, Kyung-Hun
Lee, Soo-Chin
Iwasa, Tsutomu
Iwata, Hiroji
Watanabe, Kenichi
Jung, Kyung Hae
Tanabe, Yuko
Kang, Seok Yun
Yasojima, Hiroyuki
Aogi, Kenjiro
Tokunaga, Eriko
Sim, Sung Hoon
Yap, Yoon Sim http://orcid.org/0000-0002-0347-5066
Matsumoto, Koji http://orcid.org/0000-0003-1907-0247
Tseng, Ling-Ming
Umeyama, Yoshiko http://orcid.org/0000-0003-4967-0382
Sudo, Kazuki
Kojima, Yuki http://orcid.org/0000-0002-1558-5510
Hata, Tomomi http://orcid.org/0000-0003-0400-0254
Kuchiba, Aya
Shibata, Taro
Nakamura, Kenichi
Fujiwara, Yasuhiro http://orcid.org/0000-0002-1229-5446
Tamura, Kenji
Yonemori, Kan http://orcid.org/0000-0002-7624-7611
Funding for this research was provided by:
Pfizer
Article History
Received: 28 February 2024
Accepted: 1 August 2024
First Online: 22 August 2024
Competing interests
: Authors declare no competing non-financial interests but the following competing financial interests: Emi Noguchi: speaker honoraria from AstraZeneca, Pfizer, Chugai Pharma, Novartis. Takashi Yamanaka: honoraria from AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Lilly, Kyowa Kirin, Novartis, Pfizer; consultancy/advisory fees from Daiichi Sankyo. Hirofumi Mukai: honoraria or lecture fee from Takeda and Taiho Pharmaceutical. Naohito Yamamoto: research funding from AstraZeneca and Pfizer. Chi-Feng Chung: advisory role/speaker honoraria: AstraZeneca, Daiichi Sankyo, Pfizer, Roche, and Novartis. Yen-Shen Lu: grant support/research collaborations: Novartis, Pfizer, MSD, Roche, AstraZeneca, ACT Genomics, Advisory board/speaker invitation: Novartis, Pfizer, MSD, Roche, AstraZeneca, Eisai, Eli Lily, Daiichi Sankyo and EuroPharma, Conference support: Novartis, Eisai, and MSD. Dwan-Ying Chang: advisory role/speaker honoraria: Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, MSD, Novartis, ONO pharma, Pierre-Faber, Pfizer, Roche, Sanofi, TTY Biopharm, and EuroPharma, Conference support: Pfizer, Roche, AstraZeneca, Travel accommodation: Pfizer. Joohyuk Sohn: research funding from MSD, Roche, Novartis, Lilly, Pfizer, Daiichi Sankyo, AstraZeneca, GSK, Sanofi, Boehringer Ingelheim, and Seagen. Kyung-Hun Lee: honoraria or lecture fees from AstraZeneca, Eli Lilly, Novartis, Pfizer, and Everest Medicine. Soo-Chin Lee: honoraria from Pfizer, Novartis, AstraZeneca, ACT Genomics, Lilly, MSD, Roche, Gilead Sciences, Daiichi Sankyo, DKSH; consulting/advisory fees from Pfizer, Novartis, AstraZeneca, MSD, Roche, Gilead Sciences, Daiichi Sankyo; speakers’ fees from Pfizer, Novartis, AstraZeneca, Roche, and MSD; research funding from Pfizer, Eisai, Taiho Pharmaceutical, ACT Genomics, and Karyopharm Therapeutics; travel/accommodation expenses from Amgen, Pfizer, and Roche. Hiroji Iwata: honoraria and research funding from AstraZeneca K.K. and Pfizer, fees for promotional materials from AstraZeneca. Kenichi Watanabe: speaker’s honoraria from Chugai, Eli Lilly, Nippon- Kayaku, Kyowa Kirin, Novartis, Taiho, Eisai, Pfizer, Shionogi, Daiichi Sankyo and AstraZeneca. Kyung Hae Jung: has consulting or advisory role for AstraZeneca, Bixink, Daiichi Sankyo, Eisai, Everest Medicine, MSD, Novartis, Pfizer, Roche, and Takeda Pharmaceuticals. Yuko Tanabe: research funding from MSD. Eriko Tokunaga: personal fees for lectures from Eli Lilly, AstraZeneca, and Daiichi Sankyo. Yoon Sim Yap: Honoraria: Novartis, Pfizer, Lilly/DKSH, AstraZeneca, Eisai, MSD, Specialised Therapeutics, Roche; Research funding: Merck Sharp & Dohme; Travel, accommodations, expenses: DKSH, AstraZeneca. Koji Matsumoto: has received research funding from MSD, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, and Gilead Sciences; has received honoraria from MSD, Kyowa Kirin, and Chugai. Yoshiko Umeyama: is an employee of Pfizer R&D Japan and owns stock in Pfizer. Kazuki Sudo: honoraria from AstraZeneca, Pfizer, Eisai, Nihon Medi-Physics Co.; research funding from NanoCarrier, Daiichi Sankyo, AstraZeneca, Pfizer, Amgen, PRA Health Sciences, Takeda, and Merck. Aya Kuchiba: honoraria from Chugai Pharma. Kenichi Nakamura: honoraria from Chugai Pharma, Taiho Pharmaceutical, IQVIA, AstraZeneca, Lilly; research funding from Astellas Pharma, Eisai, Otsuka, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Takeda, Chugai/Roche, Novartis, Pfizer, Bristol-Myers Squibb Japan, Boehringer Ingelheim Seiyaku, SymBio Pharmaceuticals, Merck, and Servier. Yasuhiro Fujiwara, is now Chief Executive of Pharmaceuticals and Medical Devices Agency, regulatory agency of Japan, and contributed to this trial until March 2019. Kan Yonemori: consulting/advisory fees: Chugai Pharma, Ono Pharmaceutical, Novartis, Eisai, and OncXerna Therapeutics; honoraria from Eisai, Pfizer, AstraZeneca, Novartis, Taiho Pharmaceutical, Lilly Japan, and Daiichi Sankyo/AstraZeneca. Gun Min Kim, Tsutomu Iwasa, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Sung Hoon Sim, Ling-Ming Tseng, Yuki Kojima, Tomomi Hata, Taro Shibata, and Kenji Tamura: no competing financial or non-financial interests.